Health & bio

GLP-1 Associated with Reduced Depression, Anxiety, and Addiction Risk

Large cohort data show reduced depression, anxiety, and psychiatric hospitalization rates in semaglutide and other GLP-1 users.

Primary sources · 1
ScienceDaily
Related storylines
#2026-W14-04 · GLP-1 market enters triple inflection point: oral agents, insurance cliff, and end of 503B compounding
← View the full 2026-05-06 (Wed) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →